A trial of emibetuzumab for non small cell lung cancer that had stopped responding to erlotinib (CHIME)
Cancer type:
Status:
Phase:
This trial looked at emibetuzumab for non small cell lung cancer which had spread and got worse despite having erlotinib. It was for people who had change to a 
called MET in their lung cancer cells.
It was open for people to join between 2013 and 2014. The team presented the results at a conference in 2016. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Erlotinib is a targeted treatment that doctors use to treat non small cell lung cancer (NSCLC). But sometimes it stops working and the cancer starts to grow again.
Emibetuzumab (LY2875358) is a monoclonal antibody. It can seek out cancer cells by looking for specific proteins. Researchers wanted to find out if emibetuzumab can help people whose cancer has stopped responding to erlotinib.
The people taking part were put into 1 of 2 treatment groups at random:
- half had emibetuzumab and erlotinib
- half had emibetuzumab alone
The main aim of this trial was to find out if emibetuzumab, with or without erlotinib, is useful for non small cell lung cancer. This was for people who’d already had erlotinib but their cancer had started to grow again.
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the links below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC
D. Ross Camidge and others
Presented at ASCO conference, abstract 9070.
Journal of Clinical Oncology, 2016. Volume 34, Number 15.
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (Chime)
National Library of Medicine website.
Accessed March 2024.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Denis Talbot
Supported by
Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
